MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525485 | Name: LY 181984

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LY 181984 is an antitumor sulfonylurea.

Chemical Structure

LY 181984
LY 181984
CAS#3955-50-8

Theoretical Analysis

MedKoo Cat#: 525485

Name: LY 181984

CAS#: 3955-50-8

Chemical Formula: C14H13ClN2O3S

Exact Mass: 324.0335

Molecular Weight: 324.78

Elemental Analysis: C, 51.77; H, 4.03; Cl, 10.92; N, 8.63; O, 14.78; S, 9.87

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
LY 181984; LY-181984; LY181984; MPCU.
IUPAC/Chemical Name
Benzenesulfonamide, N-(((4-chlorophenyl)amino)carbonyl)-4-methyl-
InChi Key
YOIDHZBOHMNTNP-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H13ClN2O3S/c1-10-2-8-13(9-3-10)21(19,20)17-14(18)16-12-6-4-11(15)5-7-12/h2-9H,1H3,(H2,16,17,18)
SMILES Code
O=S(C1=CC=C(C)C=C1)(NC(NC2=CC=C(Cl)C=C2)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 324.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chueh PJ, Kim C, Cho N, Morré DM, Morré DJ. Molecular cloning and characterization of a tumor-associated, growth-related, and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface. Biochemistry. 2002 Mar 19;41(11):3732-41. PubMed PMID: 11888291. 2: Morré DJ, Chueh PJ, Lawler J, Morré DM. The sulfonylurea-inhibited NADH oxidase activity of HeLa cell plasma membranes has properties of a protein disulfide-thiol oxidoreductase with protein disulfide-thiol interchange activity. J Bioenerg Biomembr. 1998 Oct;30(5):477-87. PubMed PMID: 9932650. 3: Morré DJ, Wu LY, Morré DM. Response of a cell-surface NADH oxidase to the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenylurea) (LY181984) modulated by redox. Biochim Biophys Acta. 1998 Mar 2;1369(2):185-92. PubMed PMID: 9518604. 4: Chern JW, Leu YL, Wang SS, Jou R, Lee CF, Tsou PC, Hsu SC, Liaw YC, Lin HM. Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents. J Med Chem. 1997 Jul 4;40(14):2276-86. PubMed PMID: 9216847. 5: Morré DJ, Reust T. A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-(methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients. J Bioenerg Biomembr. 1997 Jun;29(3):281-9. PubMed PMID: 9298713. 6: Morré DJ, Jacobs E, Sweeting M, de Cabo R, Morré DM. A protein disulfide-thiol interchange activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984). Biochim Biophys Acta. 1997 Apr 3;1325(1):117-25. PubMed PMID: 9106489. 7: Toth JE, Grindey GB, Ehlhardt WJ, Ray JE, Boder GB, Bewley JR, Klingerman KK, Gates SB, Rinzel SM, Schultz RM, Weir LC, Worzalla JF. Sulfonimidamide analogs of oncolytic sulfonylureas. J Med Chem. 1997 Mar 14;40(6):1018-25. PubMed PMID: 9083492. 8: Morré DJ, Wu LY, Morré DM. Inhibition of NADH oxidase activity and growth of HeLa cells by the antitumor sulfonylurea, N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) and response to epidermal growth factor. Biochim Biophys Acta. 1997 Feb 4;1355(2):114-20. PubMed PMID: 9042331. 9: Morré DJ, Wilkinson FE, Kim C, Cho N, Lawrence J, Morré DM, McClure D. Antitumor sulfonylurea-inhibited NADH oxidase of cultured HeLa cells shed into media. Biochim Biophys Acta. 1996 Apr 26;1280(2):197-206. PubMed PMID: 8639694. 10: Morré DJ. NADH oxidase activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) at an external site. Biochim Biophys Acta. 1995 Dec 13;1240(2):201-8. PubMed PMID: 8541291. 11: Morré DJ, Wu LY, Morré DM. The antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes. Biochim Biophys Acta. 1995 Nov 22;1240(1):11-7. PubMed PMID: 7495842. 12: Sun E, Lawrence J, Morré DM, Sun I, Crane FL, MacKellar WC, Morré DJ. Proton release from HeLa cells and alkalization of cytoplasm induced by diferric transferrin or ferricyanide and its inhibition by the diarylsulfonylurea antitumor drug N-(4-methylphenylsulfonyl)-N'-(4-cholorophenyl) urea (LY181984). Biochem Pharmacol. 1995 Oct 26;50(9):1461-8. PubMed PMID: 7503797. 13: Morré DJ, Wilkinson FE, Lawrence J, Cho N, Paulik M. Identification of antitumor sulfonylurea binding proteins of HeLa plasma membranes. Biochim Biophys Acta. 1995 Jun 14;1236(2):237-43. PubMed PMID: 7794962. 14: Morré DJ, Morré DM, Stevenson J, MacKellar W, McClure D. HeLa plasma membranes bind the antitumor sulfonylurea LY181984 with high affinity. Biochim Biophys Acta. 1995 May 11;1244(1):133-40. PubMed PMID: 7766649. 15: Schultz RM, Andis SL, Toth JE, Boder GB, Rinzel SM, Grindey GB. Effect of albumin on antitumor activity of diarylsulfonylureas. Anticancer Res. 1993 Nov-Dec;13(6A):1939-43. PubMed PMID: 8297099. 16: Rush GF, Rinzel S, Boder G, Heim RA, Toth JE, Ponsler GD. Effects of diarylsulfonylurea antitumor agents on the function of mitochondria isolated from rat liver and GC3/c1 cells. Biochem Pharmacol. 1992 Dec 15;44(12):2387-94. PubMed PMID: 1472104. 17: Neubauer BL, Merriman RL, Best KL, Goode RL, Sarosdy MF, Tanzer LR, Howbert JJ. Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984. J Urol. 1992 Feb;147(2):500-4. PubMed PMID: 1732631. 18: Thakar JH, Chapin C, Berg RH, Ashmun RA, Houghton PJ. Effect of antitumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions. Cancer Res. 1991 Dec 1;51(23 Pt 1):6286-91. PubMed PMID: 1933889. 19: Sosinski J, Chapin C, Thakar JH, Houghton PJ. Influence of extracellular pH on the accumulation and cytotoxicity of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human cell lines. Cancer Commun. 1991;3(12):373-81. PubMed PMID: 16296003. 20: Howbert JJ, Grossman CS, Crowell TA, Rieder BJ, Harper RW, Kramer KE, Tao EV, Aikins J, Poore GA, Rinzel SM, et al. Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships. J Med Chem. 1990 Sep;33(9):2393-407. PubMed PMID: 2391684.

View History

KML110

KML110